NeoGenomics, Inc. (NEO)

Market Cap	1.05B
Revenue (ttm)	489.31M
Net Income (ttm)	-146.82M
Shares Out	125.80M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	222.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	702,079
Open	9.04
Previous Close	8.87
Day's Range	8.23 - 9.05
52-Week Range	6.85 - 54.74
Beta	0.93
Analysts	Buy
Price Target	18.36 (+120.1%)
Earnings Date	Nov 2, 2022

About NEO

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence ...

• Industry: Life Sciences Tools & Services
• IPO Date: Nov 2, 1999
• Employees: 2,000
• Stock Exchange: NASDAQ
• Ticker Symbol: NEO

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for NEO stock is "Buy." The 12-month stock price forecast is 18.36, which is an increase of 120.14% from the latest price.

Price Target

$18.36

(120.14% upside)

Analyst Consensus: Buy

Stock Forecasts